LRRK2 p.G2019S mutation is not common among Alzheimer's disease patients in Brazil

Disease Markers

Volumn 27, Issue 1, 2009, Pages 13-16

  Santos Rebouças, Cíntia Barros ^a   Abdalla, Cláudia Bueno ^a   Martins, Paloma Águia ^a   Baldi, Fábio José Rodrigues ^a   Santos, Jussara Mendonça ^a   Motta, Luciana Branco ^a   De Borges, Margarete Borges ^b   Souza, Dorotéia Rossi Silva ^c   De Souza Pinhel, Marcela Augusta ^c   Laks, Jerson ^b   Pimentel, Márcia Mattos Gonçalves ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c Faculdade de Medicina de so José Do Rio Preto   (Brazil)

Author keywords

Alzheimer's disease; Leucine rich repeat kinase 2; LRRK2; P.G2019S mutation; Parkinson's disease

Indexed keywords

LEUCINE RICH REPEAT KINASE 2;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAZIL; FEMALE; GENE IDENTIFICATION; GENE MUTATION; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 70350501161     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2009/298182     Document Type: Article

References (23)

1. M. Albrecht, LRRK2 mutations and Parkinsonism, Lancet 365 (2005), 1230.
2. H. Brodaty and C.M. Moore, The Clock Drawing Test for dementia of the Alzheimer's type: A comparison of three scoring methods in a memory disorders clinic, Int J Geriatr Psychiatry 12 (1997), 619-627.
3. M.F. Folstein, S.E. Folstein and P.R. McHugh, "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res 12 (1975), 189-198.
4. T. Foroud, LRRK2: both a cause and a risk factor for Parkinson disease? Neurology 65 (2005), 664-665.
5. S. Goldwurm, M. Zini, L. Mariani et al., Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease, Neurology 68 (2007), 1141-1143.
6. E. Greggio, S. Jain, A. Kingsbury et al., Kinase activity is required for the toxic effects of mutant LRRK2/dardarin, Neurobiol Dis 23 (2006), 329-341.
7. D. Hernandez, C. Paisan-Ruiz, A. Crawley et al., The dardarin G2019S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases, Neurosci Lett 389 (2005), 137-139.
8. D.G. Hernandez, C. Paiśan-Rúyz, A. McInerney-Leo et al., Clinical and positron emission tomography of Parkinson's disease caused by LRRK2, Ann Neurol 57 (2005), 453-456.
9. C.C. Ho, H.J. Rideout, E. Ribe et al., The Parkinson diasease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration, J Neurosci 29 (2009), 1011-1016.
10. J. Kachergus, I.F. Mata, M. Hulihan et al., Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations, Am J Hum Genet 76 (2005), 672-680.
11. E. Lee, S. Hui, G. Ho et al., LRRK2 G2019S and I2020T mutations are not common in Alzheimer's disease and vascular dementia, Am J Med Genet B Neuropsychiatr Genet 141 (2006), 549-550.
12. I.F. Mata, W.J. Wedemeyer, M.J. Farrer et al., LRRK2 in Parkinson's disease: protein domains and functional insights, Trends Neurosci 29 (2006), 286-293.
13. J. Miklossy, T. Arai, J.P. Guo et al., LRRK2 expression in normal and pathologic human brain and in human cell lines, J Neuropathol Exp Neurol 65 (2006), 953-963.
14. B. Nolen, S. Taylor and G. Ghosh, Regulation of protein kinases; controlling activity through activation segment conformation, Mol Cell 15 (2004), 661-675.
15. M.A. Pericak-Vance, M.P. Bass, L.H. Yamaoka et al., Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12, JAMA 278 (1997), 1237-1241.
16. M.M. Pimentel, K.C. Moura, C.B. Abdalla et al., A study of LRRK2 mutations and Parkinson's disease in Brazil, Neurosci Lett 433 (2008), 17-21.
17. S. Punia, M. Behari, S.T. Govindappa et al., Absence/rarity of commonly reported LRRK2 mutations in Indian Parkinson's disease patients, Neurosci Lett 409 (2006), 83-88.
18. A. Tedde, S. Bagnoli, E. Cellini et al., No Association between the LRRK2 G2019S mutation and Alzheimer's disease in Italy, Cell Mol Neurobiol 27 (2007), 877-881.
19. M. Toft, S.B. Sando, S. Melquist et al, LRRK2 mutations are not common in Alzheimer's disease, Mech Ageing Dev 126 (2005), 1201-1205.
20. H. Tomiyama, Y. Li, M. Funayama et al., Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries, Mov Disord 21 (2006), 1102-1108.
21. A.B. West, D.J. Moore, S. Biskup et al., Parkinson's diseaseassociated mutations in leucine-rich repeat kinase 2 augment kinase activity, Proc Natl Acad Sci USA 102 (2005), 16842-16847.
22. C.P. Zabetian, C.J. Lauricella, D.W. Tsuang et al., Analysis of the LRRK2 G2019S mutation in Alzheimer Disease, Arch Neurol 63 (2006), 156-157.
23. A. Zimprich, S. Biskup, P. Leitner et al., Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology, Neuron 44 (2004), 601-607.